Portola Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
03 oct. 2017 16h05 HE
|
Portola Pharmaceuticals, Inc.
SOUTH SAN FRANCISCO, Calif., Oct. 03, 2017 (GLOBE NEWSWIRE) -- Portola Pharmaceuticals, Inc.® (NASDAQ:PTLA) announced today that on September 27, 2017, the Compensation Committee of the Board of...
Portola Announces Pricing of Public Offering of Common Stock
12 sept. 2017 22h38 HE
|
Portola Pharmaceuticals, Inc.
SOUTH SAN FRANCISCO, Calif., Sept. 12, 2017 (GLOBE NEWSWIRE) -- Portola Pharmaceuticals, Inc. (NASDAQ:PTLA) announced today the pricing of its underwritten public offering of 6,350,000 shares of its...
Portola Pharmaceuticals Announces Proposed Offering of Common Stock
11 sept. 2017 16h01 HE
|
Portola Pharmaceuticals, Inc.
SOUTH SAN FRANCISCO, Calif., Sept. 11, 2017 (GLOBE NEWSWIRE) -- Portola Pharmaceuticals, Inc.® (Nasdaq:PTLA) today announced plans to offer, subject to market and other conditions, $300 million of...
Portola Pharmaceuticals to Present at the 2017 Morgan Stanley Global Healthcare Conference
06 sept. 2017 08h00 HE
|
Portola Pharmaceuticals, Inc.
SOUTH SAN FRANCISCO, Calif., Sept. 06, 2017 (GLOBE NEWSWIRE) -- Portola Pharmaceuticals (Nasdaq:PTLA) today announced that Bill Lis, chief executive officer, will present at the 2017 Morgan Stanley...
Reminder: Portola Pharmaceuticals to Host Webcast and Conference Call Today, Tuesday, Sept. 5 to Provide Further Details on Bevyxxa® (betrixaban) Launch
05 sept. 2017 08h00 HE
|
Portola Pharmaceuticals, Inc.
SOUTH SAN FRANCISCO, Calif., Sept. 05, 2017 (GLOBE NEWSWIRE) -- Portola Pharmaceuticals (Nasdaq:PTLA) announced that it will host a webcast and conference call to provide an update on Bevyxxa®...
Portola Pharmaceuticals to Host Webcast and Conference Call Tuesday, Sept. 5 to Provide Further Details on Bevyxxa® (betrixaban) Launch
01 sept. 2017 18h34 HE
|
Portola Pharmaceuticals, Inc.
SOUTH SAN FRANCISCO, Calif., Sept. 01, 2017 (GLOBE NEWSWIRE) -- Portola Pharmaceuticals (Nasdaq:PTLA) announced that it will host a webcast and conference call to provide an update on Bevyxxa®...
Portola Pharmaceuticals Announces Upcoming Data Presentations on Betrixaban and Andexanet Alfa at the European Society of Cardiology (ESC) Congress 2017
21 août 2017 08h00 HE
|
Portola Pharmaceuticals, Inc.
SOUTH SAN FRANCISCO, Calif., Aug. 21, 2017 (GLOBE NEWSWIRE) -- Portola Pharmaceuticals Inc.® (Nasdaq:PTLA) today announced that data on betrixaban and andexanet alfa, as well as presentations on...
Portola Pharmaceuticals Announces AndexXa® (Andexanet Alfa) Biologics License Application Resubmission Accepted for Review by U.S. FDA
15 août 2017 08h00 HE
|
Portola Pharmaceuticals, Inc.
SOUTH SAN FRANCISCO, Calif., Aug. 15, 2017 (GLOBE NEWSWIRE) -- Portola Pharmaceuticals Inc.® (Nasdaq:PTLA) today announced that the U.S. Food and Drug Administration (FDA) has found its resubmitted...
Portola Pharmaceuticals Reports Second Quarter 2017 Financial Results and Provides Corporate Update
09 août 2017 16h25 HE
|
Portola Pharmaceuticals, Inc.
SOUTH SAN FRANCISCO, Calif., Aug. 09, 2017 (GLOBE NEWSWIRE) -- Portola Pharmaceuticals Inc.® (Nasdaq:PTLA) today reported financial results and provided a corporate update for the quarter ended June...
Portola Pharmaceuticals Announces Resubmission of Biologics License Application for AndexXa® (Andexanet Alfa)
03 août 2017 16h12 HE
|
Portola Pharmaceuticals, Inc.
SOUTH SAN FRANCISCO, Calif., Aug. 03, 2017 (GLOBE NEWSWIRE) -- Portola Pharmaceuticals Inc.® (Nasdaq:PTLA) today announced that on August 3, 2017 it resubmitted its Biologics License Application...